Radiation Applications

Nuclear Medicine / Curium Signs Long-Term Agreement With NRG Pallas For Lu-177 Production

By David Dalton
6 June 2024

Vital radioisotope for cancer treatments will be produced using High-Flux Reactor in Petten

Curium Signs Long-Term Agreement With NRG Pallas For Lu-177 Production
The Lu-177 will be produced using the High-Flux Reactor in Petten, the Netherlands. Courtesy NRG Pallas.
Nuclear medicine company Curium has signed a long-term agreement to extend its current partnership with NRG Pallas for new irradiation services at Petten, the Netherlands, to produce non-carrier added lutetium-177 (Lu-177).

Want to know more?
Sign up.

Pen Use this content

Tags


Related